Technical Analysis for KRON - Kronos Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Crossed Above 20 DMA | Bullish | 2.06% | |
| Crossed Above 50 DMA | Bullish | 2.06% | |
| 180 Bullish Setup | Bullish Swing Setup | 2.06% | |
| Bollinger Band Squeeze | Range Contraction | 2.06% | |
| Fell Below 20 DMA | Bearish | 5.32% | |
| Fell Below 50 DMA | Bearish | 5.32% | |
| 180 Bearish Setup | Bearish Swing Setup | 5.32% |
| Alert | Time |
|---|---|
| Up 2% | about 21 hours ago |
| Bullish 180 Entry | about 21 hours ago |
| Rose Above Previous Day's High | about 21 hours ago |
| Up 1% | about 21 hours ago |
| 50 DMA Resistance | about 22 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Solid Tumors Acute Myeloid Leukemia Enzymes Tyrosine Kinase Transcription Cancer Therapeutics Transcription Factors Novel Cancer Transcription Factor Cyclin Dependent Kinase Entospletinib Morpholines
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Solid Tumors Acute Myeloid Leukemia Enzymes Tyrosine Kinase Transcription Cancer Therapeutics Transcription Factors Novel Cancer Transcription Factor Cyclin Dependent Kinase Entospletinib Morpholines
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.6 |
| 52 Week Low | 0.69 |
| Average Volume | 74,389 |
| 200-Day Moving Average | 1.07 |
| 50-Day Moving Average | 0.97 |
| 20-Day Moving Average | 0.95 |
| 10-Day Moving Average | 0.96 |
| Average True Range | 0.06 |
| RSI (14) | 53.92 |
| ADX | 19.47 |
| +DI | 10.28 |
| -DI | 13.01 |
| Chandelier Exit (Long, 3 ATRs) | 0.81 |
| Chandelier Exit (Short, 3 ATRs) | 1.04 |
| Upper Bollinger Bands | 1.00 |
| Lower Bollinger Band | 0.91 |
| Percent B (%b) | 0.87 |
| BandWidth | 10.08 |
| MACD Line | 0.00 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.0056 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.10 | ||||
| Resistance 3 (R3) | 1.08 | 1.04 | 1.08 | ||
| Resistance 2 (R2) | 1.04 | 1.01 | 1.04 | 1.07 | |
| Resistance 1 (R1) | 1.01 | 0.99 | 1.03 | 1.03 | 1.07 |
| Pivot Point | 0.97 | 0.97 | 0.97 | 0.97 | 0.97 |
| Support 1 (S1) | 0.94 | 0.94 | 0.96 | 0.96 | 0.91 |
| Support 2 (S2) | 0.90 | 0.92 | 0.90 | 0.91 | |
| Support 3 (S3) | 0.87 | 0.90 | 0.90 | ||
| Support 4 (S4) | 0.89 |
